Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus

JAMA

Volumn 297, Issue 18, 2007, Pages 2010-2017

  Giordano, Thomas P ^a,b   Henderson, Louise ^a,b   Landgren, Ola ^c   Chiao, Elizabeth Y ^a,b   Kramer, Jennifer R ^a,b   El Serag, Hashem ^a,b   Engels, Eric A ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THYROID CANCER; THYROIDITIS; UNITED STATES; VETERAN; WALDENSTROEM MACROGLOBULINEMIA;

EID: 34248399089     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.18.2010     Document Type: Article

References (27)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
2. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41:88-96.
3. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89-94.
4. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer. 1996;77:2604-2613.
5. Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer. 2004;111:76-80.
6. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer. 2004;111:1-8.
7. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490-1495.
8. Montella M, Crispo A, Pezzullo L, et al. Is hepatitis C virus infection associated with thyroid cancer? a case-control study. Int J Cancer. 2000;87:611-612.
9. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf). 1999;50:503-509.
10. Fujino Y, Tamakoshi A, Hoshiyama Y, et al. Prospective study of transfusion history and thyroid cancer incidence among females in Japan. Int J Cancer. 2004;112:722-725.
11. Duberg AS, Nordstrom M, Torner A, et al. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology. 2005;41:652-659.
12. Amin J, Dore GJ, O'Connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol. 2006;45:197-203.
13. Page WF, Mahan CM, Kang HK. Vital status ascertainment through the files of the Department of Veterans Affairs and the Social Security Administration. Ann Epidemiol. 1996;6:102-109.
14. Fisher SG, Weber L, Goldberg J, Davis F. Mortality ascertainment in the veteran population: alternatives to the National Death Index. Am J Epidemiol. 1995;141:242-250.
15. Izumi T, Sasaki R, Shimizu R, et al. Hepatitis C virus infection in Waldenstrom's macroglobulinemia.Am J Hematol. 1996;52:238-239.
16. Veneri D, Aqel H, Franchini M, Meneghini V, Krampera M. Prevalence of hepatitis C virus infection in IgM-type monoclonal gammopathy of uncertain significance and Waldenstrom macroglobulinemia [letter]. Am J Hematol. 2004;77:421.
17. Santini GF, Crovatto M, Modolo ML, et al. Waldenstrom macroglobulinemia: a role of HCV infection [letter]? Blood. 1993;82:2932.
18. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369.
19. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938-941.
20. Machida K, Cheng KT, Pavio N, Sung VM, Lai MM. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol. 2005;79:8079-8089.
21. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078-2085.
22. Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection [letter]. JAMA. 1999;281:1588.
23. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med. 2004;164:2371-2376.
24. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312:601-604.
25. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439-1445.
26. Harris RE, Hebert JR, Wynder EL. Cancer risk in male veterans utilizing the Veterans Administration medical system. Cancer. 1989;64:1160-1168.
27. Namboodiri KK, Harris RE. Hematopoietic and lymphoproliferative cancer among male veterans using the Veterans Administration Medical System. Cancer. 1991;68:1123-1130.